Autopsy report · NCT00408070

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

“Did not meet accrual goals.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 3 years before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

UConn Health

Sponsor type

University, hospital or other

Conditions

Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Stage 3 Cancer; Stage 4 Cancer

Interventions

Bevacizumab; Carboplatin; Paclitaxel

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
  “Failure to meet accrual goals.” (70% match in meaning)
• Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
  “Did not meet enrollment goals.” (66% match in meaning)
• Comminuted Intra-Articular Distal Tibia Fracture Fixation Using Computer Techniques
  “Enrollment goal was not met.” (65% match in meaning)
• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (64% match in meaning)
• A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
  “Accrual goal met” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.